COVID-19 Research Paper Volume 13, Issue 17 pp 20906—20914

High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study

Changes in inflammatory markers levels from baseline to day 21 during hospitalization. The levels of high-sensitivity C-reactive protein (hs-CRP, A), Interleukin-6 (IL-6, B), IL-8 (C), and tumor necrosis factor-α (TNF-α, D) at day 21 during hospitalization in patients administered with high-dose intravenous vitamin C (HIVC, n = 51) significantly decreased compared with those receiving symptomatic supportive treatments alone (n = 62). In addition, changes of the inflammatory markers levels displayed a tendency of significant decrease at day 21 during hospitalization related to baseline in patients underwent HIVC therapy.

Figure 3. Changes in inflammatory markers levels from baseline to day 21 during hospitalization. The levels of high-sensitivity C-reactive protein (hs-CRP, A), Interleukin-6 (IL-6, B), IL-8 (C), and tumor necrosis factor-α (TNF-α, D) at day 21 during hospitalization in patients administered with high-dose intravenous vitamin C (HIVC, n = 51) significantly decreased compared with those receiving symptomatic supportive treatments alone (n = 62). In addition, changes of the inflammatory markers levels displayed a tendency of significant decrease at day 21 during hospitalization related to baseline in patients underwent HIVC therapy.